在其他近期新闻中，Processa Pharmaceuticals, ...

Processa Pharmaceuticals has a one year low of $0.40 and a one year high of $3.31. The company has a market capitalization of $1.39 million, a price-to-earnings ratio of -0.13 and a beta of 0.75 ...

Management will present a corporate overview on Friday, March 28 th at 9:40 a.m. Eastern time, and will hold one-on-one meetings with registered investors and other attendees throughout the conference ...

In this article, we are going to take a look at where Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) stands against the other cheap stocks insiders are buying recently. Why should we be interested ...

Processa Pharmaceuticals Inc. (PCSA) shares have tumbled to a 52-week low, touching down at $0.8, marking a significant downturn for the micro-cap company currently valued at just $2.68 million.

David Young, the President of Research & Development at Processa Pharmaceuticals , Inc. (NASDAQ:PCSA), has increased his stake in the company with a recent purchase of common stock. According to a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investing.com - Processa Pharmaceuticals (NASDAQ: PCSA) reported first quarter EPS of $-0.810, $0.49 worse than the analyst estimate of $-0.320. Revenue for the quarter came in at... ByInvesting ...

Financial Health for Processa Pharmaceuticals is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Developed economic markets.

We recently published a list of 10 Cheapest Stocks Insiders Are Buying Recently. In this article, we are going to take a look at where Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) stands against the ...